John D.RobertsMD

PubMed

• Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease.
  Raghda T Fouda, Hemanth M Cherukury, Stacy B Kiven, Natalie R Garcia, Donovan A Argueta
  Haematologica. 2024-01-01
• 4 citations
  Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy.
  Susanna A Curtis, Balbuena-Merle Raisa, John D. Roberts, Jeanne E. Hendrickson, Joanna L. Starrels
  Transfusion and Apheresis Science. 2021-10-30
• 5 citations
  Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
  Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep S. Dave, Prithviraj Bose
  Leukemia & Lymphoma. 2021-04-16

Journal Articles

• The relationship between taste, olfaction, and nutrition in the cancer population  
  Farmer MN, Raddin RS, Roberts JD, J Supportive Onco, 3/1/2009
• Daily assessment of pain in adults with sickle cell disease  
  Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD, Ann Intern Med., 1/15/2008
• Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo  
  Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P, Mol Cancer Ther., 1/1/2008
• Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES Project  
  Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, Citero VD, Penberthy LT, Aisiku IP, Roberts JD, Roseff SD, Smith WR, Psychosom Med., 12/24/2007
• Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer ...  
  Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P, Mol Cancer Ther., 12/1/2007
• E2F1 amplification and genetic heterogeneity in melanoma  
  Roberts JD, Cancer Biol Ther, 1/1/2006
• Gender differences in pain and health care utilization for adult sickle cell patients: the PiSCES project  
  McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD, Aisiku IP, Smith WR, Journal of Women’s Health, 1/1/2006
• Phase I study of bryostatin 1 and fludarabine in patients with chroniclymphocytic leukemia and indolent (non-Hodgkin's) lymphoma  
  Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S, Clin Cancer Res, 1/1/2006
• Phase 2 Study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901  
  Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; for the Cancer and L..., J. Immunother., 1/1/2006
• Understanding pain and improving management of sickle cell disease: the PiSCES Study  
  Smith, WR, Bovbjeg, VE, Penberthy, LT, McClish, DK, Levenson, JL, Roberts, JD, Gil, K, Roseff, SD, Aisiku, IP, Journal of the National Medical Association, 1/1/2005
• Transient Exposure of Mammary Tumors to PD184352 and UCN-01 Causes Tumor Cell Death In Vivo and Prolonged Suppression of Tumor Regrowth  
  Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P, Cancer Biol Ther, 1/1/2005
• The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy  
  Grant S, Roberts JD, Drug Resistance Updates, 1/1/2003
• Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma  
  Levine, EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ, Cancer, 1/1/2003
• Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model  
  McClish DK, Roberts JD, Investigational New Drugs, 1/1/2003
• Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial  
  Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN, Br J Haematol., 1/1/2003
• Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia  
  Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S, Clin Cancer Res, 1/1/2002
• Novel approaches to polynuclear platinum pro-drugs Selective release of cytotoxic platinum-spermidine species through hyrolytic cleavage of carbamates  
  Hegmans A, Qu Y, Kelland LR, Roberts JD, Farrell N, Inorg Chem, 1/1/2001
• Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: A pilot clinical trial  
  Bear HD, Roberts JD, Cornell D, Tombes MB, Kyle B, Cancer Immunol Immunoth, 1/1/2001
• Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect  
  hman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN, Arterioscler Thromb Vasc Biol, 1/1/2001
• A phase I study of RSR13, radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics  
  Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, PearlmanAD, Shaw EG, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ, Int J Radiat Oncol Biol Phys., 1/1/2001
• Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer  
  Hillner BE, Roberts, JD, J Natl Cancer Inst, 1/1/2000
• Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks  
  Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso L, Clendeninn NJ, Cancer Chemother Pharmacol, 1/1/2000
• Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation  
  Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant SG, Synold T, Moran R, Cancer Chemother Pharmacol, 1/1/2000
• Pharmacokinetic and pharmacodynamic evaluation of the GARFT inhibitor AG2034  
  McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD, Clin Cancer Res, 1/1/2000
• A multicenter phase II trial of losoxantrone (DUP-941) in hormone-refractory metastatic prostate cancer  
  Huan SD, Natale RB, Stewart DJ, Sartiano GP, Stella PJ, Roberts JD, Symes AL, Finizio M, Clin Cancer Res, 1/1/2000
• Join now to see all

Books/Book Chapters

• The Biology of Nitric Oxide (Proceedings of the Second International Meeting on the Biology of Nitric Oxide) 
  Chapter: Mechanism of Interleukin-2 Induced Hypotension in Humans: Activation of the Nitric Oxide/Cyclic GMP Pathway. 
  Roberts, JD, Moore AL, Hacker MP, Huot AEEditors: Moncada S, Marletta MA, Hibbs JB, Jr, Higgs EA.Portland Press, Colchester, United Kingdom1992
• Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 
  Chapter: Cisplatin Efficacy and Toxicity:Are they Separable? 
  Hacker MP, Roberts JDEditors: Nicolini M and Bandoli G.Martinus Nijhoff Publishing, Boston1988

Abstracts/Posters

• Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
  John D. Roberts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease
  John D. Roberts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• What is “research” in clinical research and who should pay for it? 
  9/27/2011
• The VCU Adult Sickle Cell Program: service and research. 
  Yale University - 9/19/2011
• A new phase II trial design for the era of targeted agents. 
  University of Vermont - 8/17/2010
• A new approach to phase II trials. 
  1/12/2008
• Phase Ib trial of bryostatin and interleukin-2 in melanoma and renal cell cancer. 
  3/10/2003
• Phase I trial of lometrexol. 
  University of North Carolina at Chapel Hill - 1/12/1998
• Platinum complexes: Clinical and related Studies. 
  5/22/1993
• Aspects of developmental therapeutics at the Vermont Cancer Center. 
  Virginia Commonwealth University - 2/13/1993
• Join now to see all